Lupus News and Research

Latest Lupus News and Research

Viral Genetics to develop drug therapies for immune-related disorders and diseases

The University of Colorado and Viral Genetics Inc., recently executed an exclusive license agreement that expands on its previous agreement allowing Viral Genetics to develop treatments for autoimmune diseases, graft rejection, HIV, and cancer based on the work of M. Karen Newell, Ph.D., a professor of biology at the University of Colorado at Colorado Springs.

4 Dec 2009

Research shows link between nervous and immune systems; findings may lead to new treatments for autoimmune disorders

New research in the Journal of Leukocyte Biology shows the link between the nervous and immune systems and how breaking that link might lead to new treatments for a wide range of autoimmune disorders

1 Dec 2009

GIS scientists publish the first genetic historical map of Han Chinese

The first genetic historical map of the Han Chinese, the largest ethnic population in the world, as they migrated from south to north over evolutionary time was published online today by the American Journal of Human Genetics by scientists at the Genome Institute of Singapore (GIS).

26 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.

24 Nov 2009

Medical advances abound while surgeons report concerns about medical errors

The Wall Street Journal reports on "20 health-care advances to give thanks for this Thanksgiving." Among the most key: "Life expectancy in the U.S. reached an all-time high of 77.9 years in 2007, the latest year for which statistics are available, continuing a long upward trend. (That's 75.3 years for men and 80.4 years for women.) ... Death rates dropped significantly for eight of the 15 leading causes of death in the U.S., including cancer, heart disease, stroke, hypertension, accidents, diabetes, homicides and pneumonia, from 2006 to 2007."

24 Nov 2009

LFAGW celebrates 35th anniversary

The Lupus Foundation of America Greater Washington Chapter (LFAGW) will celebrate 35 years of success providing free day-to-day education, advice and resources for the 75,000+ people with lupus and their families in the greater D.C. area.

24 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

SCF founder Sabrina Cohen recognized as a WebMD 2009 Health Hero

Sabrina Cohen, founder of The Sabrina Cohen Foundation for Stem Cell Research (SCF), was just recognized as a WebMD 2009 Health Hero. She will receive national media attention with a full-page article about her personal story of triumph and courage, and shares the spotlight with celebrity movie-star, Scarlett Johansson and other Health Heroes in the November/December issue.

20 Nov 2009

Final results from ImmuPharma's Phase IIb trial of LUPUZOR

ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.

19 Nov 2009

Protein content of women's saliva changes with advancing age, describe scientists

In a step toward using human saliva to tell whether those stiff joints, memory lapses, and other telltale signs of aging are normal or red flags for disease, scientists are describing how the protein content of women's saliva change with advancing age.

19 Nov 2009

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others.

18 Nov 2009

Cold weather can trigger Raynaud's disease

Cold weather triggers a painful and sometimes debilitating disorder for millions of Americans who suffer from Raynaud's disease (also known as Raynaud's syndrome or phenomenon). Raynaud's is an autoimmune disorder in which spasms in the blood vessels can interrupt blood flow to the fingers, toes, nose and ears. Exposure to cold triggers the spasms, typically causing the affected area to turn white, then blue, then bright red. Emotional stress can also cause an attack.

17 Nov 2009

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.

16 Nov 2009

Tips for treating age-related dermatologic concerns

Everyone expects their bodies to change as they get older. From wrinkles and sagging skin to brittle bones and aches and pains, the aging process is inevitable. In addition, there are a number of medical dermatologic conditions that surface with age that can cause people even more stress. Fortunately, dermatologists can help diagnose and treat these conditions no matter when they strike.

11 Nov 2009

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

7 Nov 2009

Study on asbestos-related diseases in Libby launched

Over nearly a century, thousands of residents and workers in Libby, MT, have been exposed to asbestos-contaminated vermiculite ore, leading to markedly higher rates of lung disease and autoimmune disorders, and causing to Libby in 2002 to be added to the federal Environmental Protection Agency's "National Priorities List."

4 Nov 2009

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States.

2 Nov 2009

Lupus News and Research

Latest Lupus News and Research

Viral Genetics to develop drug therapies for immune-related disorders and diseases

Research shows link between nervous and immune systems; findings may lead to new treatments for autoimmune disorders

GIS scientists publish the first genetic historical map of Han Chinese

Human Genome Sciences submits BLA for ZALBIN

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

Medical advances abound while surgeons report concerns about medical errors

LFAGW celebrates 35th anniversary

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

SCF founder Sabrina Cohen recognized as a WebMD 2009 Health Hero

Final results from ImmuPharma's Phase IIb trial of LUPUZOR

Protein content of women's saliva changes with advancing age, describe scientists

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Cold weather can trigger Raynaud's disease

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Tips for treating age-related dermatologic concerns

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

Study on asbestos-related diseases in Libby launched

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

Interim data from Schering-Plough's narlaprevir Phase IIa study

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Lupus News and Research

Latest Lupus News and Research

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Newsletters you may be interested in